Research shows how resistant starch could slow down progression of non-alcoholic fatty liver disease

The prebiotic resistant starch could play an important role in the treatment of non-alcoholic fatty liver disease (NAFLD) in the future.

Explosive Hazard Identification in Pharmaceutical Process Development

Scitegrity, a leading company in chemical regulatory compliance, is excited to announce the expanded release of its Dangerous Goods Assessor for Pharmaceutical Process Development and

September 1, 2023

UCB’s BIMZELX gains FDA approval for inflammatory conditions

The product is indicated to treat active psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis. Credit: Oporty786/Shutterstock. Biopharmaceutical company UCB has received US Food and

September 24, 2024

New funding from Breast Cancer Now supports research on treatment-resistant ER-positive breast cancer

Researchers are investigating how the most common type of breast cancer resists hormone therapy, thanks to new funding from Breast Cancer Now.

October 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.